Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Condition(s):Small-cell Lung Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Small Cell CarcinomaLast Updated:March 19, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Small-cell Lung Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Small Cell CarcinomaLast Updated:March 19, 2024Recruiting
Condition(s):Small Cell Lung Cancer Extensive Stage; Large Cell Neuroendocrine Carcinoma of the LungLast Updated:February 9, 2024Recruiting
Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:August 31, 2023Recruiting
Condition(s):Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; CarcinomaLast Updated:February 6, 2018No longer available
Condition(s):Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; CarcinomaLast Updated:August 20, 2021Completed
Condition(s):Small Cell Lung Cancer (SCLC); Neuroendocrine (NE) Tumors; Large Cell Neuroendocrine (NE) TumorsLast Updated:October 17, 2019Withdrawn
Condition(s):Non-Small Cell Lung CarcinomaLast Updated:October 31, 2013Terminated
Condition(s):Non-Small-Cell Lung Carcinoma; Carcinoma, BronchogenicLast Updated:April 3, 2009Completed
Condition(s):Non-small-cell Lung CancerLast Updated:December 7, 2017Terminated
Condition(s):Neuroendocrine Tumors; Carcinoma, Small Cell Lung; Neuroendocrine CarcinomaLast Updated:December 14, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.